ADHD Treatment-Selection Boundary

Definition

The ADHD treatment-selection boundary is the episode’s rule that medication, behavioral therapy, daily structure, and adjuncts must be matched to the person’s impairment, preferences, medical and psychiatric risks, response, and monitoring needs rather than ranked as one universal protocol.

Current Synthesis

John Kruse presents stimulants as the strongest medication class in the episode while distinguishing amphetamine products from methylphenidate and refusing a rigid one-path sequence. Potential benefit has to be weighed against sleep, appetite, cardiovascular, growth, rebound, misuse, psychosis, and substance-use context. Personal or family psychosis history is especially important in the source’s amphetamine boundary, while cardiac history can change evaluation and monitoring.

The wider menu is not flat. Guanfacine and clonidine are slower alpha-2 agonist options with sedation and discontinuation considerations; modafinil can support alertness but is not presented as equally helpful for most ADHD patients. CBT and external structure have practical roles, whereas caffeine, nicotine, cannabis, fish oil, neurofeedback, and game-like tools carry mixed evidence, narrower effects, or meaningful harms. The synthesis is shared selection and follow-up, not self-medication or abrupt discontinuation.

Key Claims

• Medication choice should follow individualized risk-benefit discussion and patient preference rather than one rigid sequence.
• Amphetamine and methylphenidate formulations differ in mechanism, average efficacy, duration, rebound pattern, and risk profile.
• Psychiatric history, especially personal or family psychosis, can materially change stimulant selection.
• Cardiovascular history, blood pressure, heart rate, sleep, appetite, growth, mood, and misuse risk can affect monitoring.
• Guanfacine, clonidine, and modafinil are distinct options rather than generic substitutes for stimulants.
• Behavioral structure and ADHD-adapted CBT can complement medication and remain relevant when medication helps.
• Caffeine, nicotine, cannabis, fish oil, neurofeedback, and game-like attention tools should not be treated as equivalent evidence-based replacements.

Evidence

• Shared selection - Improve Focus With Behavioral Tools & Medication for ADHD | Dr. John Kruse has Kruse describe discussing benefits and risks and listening to patient preferences.
• Stimulant distinctions - Improve Focus With Behavioral Tools & Medication for ADHD | Dr. John Kruse contrasts methylphenidate, amphetamine products, immediate and extended release, and lisdexamfetamine’s prodrug design.
• Psychiatric and cardiac boundaries - Improve Focus With Behavioral Tools & Medication for ADHD | Dr. John Kruse discusses psychosis history, rare stimulant-associated psychosis, blood pressure, heart rate, family history, and selective EKG use.
• Non-stimulants - Improve Focus With Behavioral Tools & Medication for ADHD | Dr. John Kruse distinguishes alpha-2 agonists and modafinil by mechanism, timing, sedation, approved uses, and expected ADHD response.
• Adjunct uncertainty - Improve Focus With Behavioral Tools & Medication for ADHD | Dr. John Kruse keeps fish oil, microbiome guidance, neurofeedback, video-game transfer, exercise prescriptions, cannabis, nicotine, and caffeine qualified.

Counterevidence & Qualifications

This page summarizes one public interview, not prescribing guidance. The episode’s comparative efficacy, psychosis frequency, blood-pressure change, growth effect, addiction-risk, fish-oil dose, cannabis, nicotine, caffeine, and drug-holiday claims require independent clinical evidence and patient context. No one should start, stop, combine, or change prescription drugs or psychoactive substances from this summary; clonidine discontinuation and stimulant psychiatric or cardiovascular effects are specifically presented as issues requiring professional oversight.

What Changed

• Added a shared-selection framework across stimulant, non-stimulant, behavioral, substance, and supplement options.
• Made psychiatric, cardiovascular, discontinuation, and evidence-quality boundaries explicit.

Related Concepts

• ADHD External Structure and Timing - behavioral infrastructure that can complement clinical treatment.
• ADHD Self-Diagnosis Boundary / ADHD 自诊边界 - diagnostic gate that precedes treatment choice.
• Medical Risk Management - general framework for matching intervention benefit to patient-specific harm.
• Dopamine Inverted U - adjacent caution that more stimulation does not imply uniformly better cognition.
• Substance Sleep Architecture Boundary - sleep-related substance boundary relevant to treatment context.
• Acetylcholine Focus Support - adjacent nicotine and attention branch requiring safety qualification.